Isomorphic Labs, the London-based AI drug discovery company spun out of Google DeepMind in 2021, has successfully closed a US$2.1 billion funding round. The Investment was led by Thrive Capital, with participation from its parent company Alphabet, as well as MGX, Temasek, CapitalG, GV, and the UK Sovereign AI Fund.
The company plans to utilize the capital to significantly expand its proprietary AI drug design engine, IsoDDE, and to scale its workforce across AI, engineering, drug design, and CLInical development teams. While Isomorphic Labs has established high-profile partnerships with phArmaceutical giants such as Eli Lilly and Novartis, the AI-driven drug discovery sector has yet to bring an APProved medicine to market, and very few projects have advanced to clinical trials.
Comments & Questions (0)
No comments yet
Be the first to comment!